Peptide vaccines for myeloid leukaemias
- PMID: 18790445
- DOI: 10.1016/j.beha.2008.05.001
Peptide vaccines for myeloid leukaemias
Abstract
The development of cancer vaccines directed against myeloid leukaemias has been a research area of intense interest in the past decade. Both human studies in vitro and mouse models in vivo have demonstrated that leukaemia-associated antigens (LAAs), such as the fusion protein BCR-ABL, Wilms' tumour protein and proteinase 3, may serve as effective targets for cellular immunotherapy. Peptide-based vaccines are able to induce cytotoxic T-lymphocyte responses that kill leukaemia cells. Based on these results, pilot clinical trials have been initiated in chronic and acute myeloid leukaemia and other haematological malignancies, which include vaccination of patients with synthetic peptides derived from these LAAs. Results from these trials show that peptide vaccines are able to induce immune responses that are sometimes associated with clinical benefit. These early clinical results are promising and provide valuable information for future improvement of the vaccines. This chapter will focus mainly on discussing the preclinical studies of peptide vaccines in human systems, the results from clinical trials and the future prospects for vaccine therapy for myeloid leukaemia.
Similar articles
-
[Immunotherapy and cell therapy for myeloid leukemia].Nihon Rinsho. 2009 Oct;67(10):1938-43. Nihon Rinsho. 2009. PMID: 19860194 Review. Japanese.
-
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Clin Exp Immunol. 2007 May;148(2):189-98. doi: 10.1111/j.1365-2249.2007.03383.x. Clin Exp Immunol. 2007. PMID: 17437417 Free PMC article. Review.
-
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.Cancer Res. 2007 Jun 1;67(11):5300-7. doi: 10.1158/0008-5472.CAN-06-3737. Cancer Res. 2007. PMID: 17545610
-
A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias.Leukemia. 2006 Jun;20(6):1067-72. doi: 10.1038/sj.leu.2404234. Leukemia. 2006. PMID: 16628186
-
Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.Exp Hematol. 2006 Dec;34(12):1709-19. doi: 10.1016/j.exphem.2006.07.009. Exp Hematol. 2006. PMID: 17157168
Cited by
-
Tumour-associated antigens: considerations for their use in tumour immunotherapy.Int J Hematol. 2011 Mar;93(3):263-273. doi: 10.1007/s12185-011-0783-1. Epub 2011 Mar 1. Int J Hematol. 2011. PMID: 21360066 Review.
-
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.Immunol Cell Biol. 2011 Mar;89(3):396-407. doi: 10.1038/icb.2010.124. Epub 2011 Feb 8. Immunol Cell Biol. 2011. PMID: 21301477 Free PMC article. Review.
-
Tumor vaccines and beyond.Cytotherapy. 2011 Jan;13(1):8-18. doi: 10.3109/14653249.2010.530649. Epub 2010 Nov 10. Cytotherapy. 2011. PMID: 21067312 Free PMC article. Review.
-
Immunotherapy: opportunities, risks and future perspectives.Cytotherapy. 2014 Apr;16(4 Suppl):S120-9. doi: 10.1016/j.jcyt.2014.02.001. Cytotherapy. 2014. PMID: 24629797 Free PMC article. Review.
-
Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):e2100588118. doi: 10.1073/pnas.2100588118. Proc Natl Acad Sci U S A. 2021. PMID: 34074778 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
